Author

Tanner J. Schumacher

University of Minnesota, DuluthORCID 0000-0002-7315-6140Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Organism:human· 1 Research Focus:metabolism & bioenergetics· 1 Organism:mouse· 1

Frequent Co-Authors

Conor T. RonayneiD· 3 shared Venkatram R. MereddyiD· 3 shared Jon N. RumbleyiD· 2 shared Ananth V. Iyer· 1 shared Grant W. Anderson· 1 shared Johnson, Joseph L., Jr.· 1 shared Kayla M. Johnson· 1 shared Matthew D. Wittmer· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Conor T. RonayneORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Nitroxoline-O-protected derivatives inhibit MetAP2 and activate ATF4 through mTORC1 to inhibit cancer cell growth

Michael J. Williams, Conor T. Ronayne, Tanner J. Schumacher, Kayla M. Johnson, Matthew D. Wittmer, Johnson, Joseph L., Jr., Grant W. Anderson, Venkatram R. Mereddy

The paper synthesizes nitroxoline analogs that inhibit MetAP2 and activate ATF4 via mTORC1, showing anti-cancer effects in vitro.

Bioorganic & Medicinal Chemistry Letters · Mar 28, 2026Peer-reviewedCancer Biology

Development of fluoro-7-aminocarboxycoumarin-based mitochondrial pyruvate carrier inhibitors as anticancer agents

Tanner J. Schumacher, Zachary S. Gardner, Jon N. Rumbley, Conor T. Ronayne, Venkatram R. Mereddy

The paper develops novel fluoro-substituted aminocarboxycoumarin derivatives as mitochondrial pyruvate carrier inhibitors with anticancer potential.

Journal of Biological Chemistry · Jul 16, 2025Peer-reviewedCancer Biology

Repurposing mitochondrial-targeting anthelmintic agents with GLUT1 inhibitor BAY-876 for cancer therapy

Tanner J. Schumacher, Ananth V. Iyer, Jon N. Rumbley, Conor T. Ronayne, Venkatram R. Mereddy

This study combines mitochondrial-targeting anthelmintics with a GLUT1 inhibitor to target cancer metabolism, showing enhanced efficacy by disrupting both glycolysis and mitochondrial respiration in breast cancer cells.

BMC Cancer · Nov 16, 2024Peer-reviewedCancer Biology